Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Licia Rivoltini

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Anatomy

Physiology

Procedures

Immunotherapy

Genes & Molecular Sequences

Amino Acid Sequence

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Bigioni Mario; Parlani Massimo; Bressan Alessandro; Bellarosa Daniela; Rivoltini Licia; Animati Fabio; Crea Attilio; Bugianesi Rossana; Maggi Carlo Alberto; Manzini Stefano; Binaschi Monica
Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants.
Pilla Lorenzo; Rivoltini Licia; Patuzzo Roberto; Marrari Andrea; Valdagni Riccardo; Parmiani G
Multipeptide vaccination in cancer patients.
Daniotti Maria; Ferrari Andrea; Frigerio Simona; Casieri Paola; Miselli Francesca; Zucca Elisa; Collini Paola; Della Torre Gabriella; Manoukian Siranoush; Peissel Bernard; Bono Aldo; Santinami Mario; Parmiani Giorgio; Rivoltini Licia; Pilotti Silvana; Rodolfo Monica
Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Licia Rivoltini (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Bigioni Mario; Parlani Massimo; Bressan Alessandro; Bellarosa Daniela; Rivoltini Licia; Animati Fabio; Crea Attilio; Bugianesi Rossana; Maggi Carlo Alberto; Manzini Stefano; Binaschi Monica
Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants.
International journal of cancer. Journal international du cancer 2009;125(10):2456-64.
2009: Pilla Lorenzo; Rivoltini Licia; Patuzzo Roberto; Marrari Andrea; Valdagni Riccardo; Parmiani G
Multipeptide vaccination in cancer patients.
Expert opinion on biological therapy 2009;9(8):1043-55.
2009: Daniotti Maria; Ferrari Andrea; Frigerio Simona; Casieri Paola; Miselli Francesca; Zucca Elisa; Collini Paola; Della Torre Gabriella; Manoukian Siranoush; Peissel Bernard; Bono Aldo; Santinami Mario; Parmiani Giorgio; Rivoltini Licia; Pilotti Silvana; Rodolfo Monica
Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT.
The Journal of investigative dermatology 2009;129(7):1759-68.
2009: Iero Manuela; Filipazzi Paola; Castelli Chiara; Belli Filiberto; Valdagni Riccardo; Parmiani Giorgio; Patuzzo Roberto; Santinami Mario; Rivoltini Licia
Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?
Cancer immunology, immunotherapy : CII 2009;58(7):1159-67.
2009: Martayan Aline; Sibilio Leonardo; Tremante Elisa; Monaco Elisa Lo; Mulder Arend; Fruci Doriana; Cova Agata; Rivoltini Licia; Giacomini Patrizio
Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells.
Journal of immunology (Baltimore, Md. : 1950) 2009;182(6):3609-17.
2009: Logozzi Mariantonia; De Milito Angelo; Lugini Luana; Borghi Martina; Calabrò Luana; Spada Massimo; Perdicchio Maurizio; Marino Maria Lucia; Federici Cristina; Iessi Elisabetta; Brambilla Daria; Venturi Giulietta; Lozupone Francesco; Santinami Mario; Huber Veronica; Maio Michele; Rivoltini Licia; Fais Stefano
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients.
PloS one 2009;4(4):e5219.
2008: Maccalli Cristina; Di Cristanziano Veronica; Fodale Valentina; Corsi Domenico; D'Agostino Giuseppina; Petrangeli Valentina; Laurenti Luca; Guida Sofia; Mazzocchi Arabella; Arienti Flavio; Perrone Maria P; Castelli Chiara; Rivoltini Licia; Zagonel Vittorina; Tartaglia Marco; Parmiani Giorgio; Belardelli Filippo
Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7292-303.
2008: De Filippo AnnaMaria; Binder Robert J; Camisaschi Chiara; Beretta Valeria; Arienti Flavio; Villa Antonello; Della Mina Pamela; Parmiani Giorgio; Rivoltini Licia; Castelli Chiara
Human plasmacytoid dendritic cells interact with gp96 via CD91 and regulate inflammatory responses.
Journal of immunology (Baltimore, Md. : 1950) 2008;181(9):6525-35.
2008: Casati Chiara; Camisaschi Chiara; Novellino Luisa; Mazzocchi Arabella; Triebel Frédéric; Rivoltini Licia; Parmiani Giorgio; Castelli Chiara
Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(6):3782-8.
2008: Vallacchi Viviana; Daniotti Maria; Ratti Francesca; Di Stasi Delia; Deho Paola; De Filippo Annamaria; Tragni Gabrina; Balsari Andrea; Carbone Antonino; Rivoltini Licia; Parmiani Giorgio; Lazar Noureddine; Perbal Bernard; Rodolfo Monica
CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma.
Cancer research 2008;68(3):715-23.
2008: Iero M; Valenti R; Huber V; Filipazzi P; Parmiani G; Fais S; Rivoltini L
Tumour-released exosomes and their implications in cancer immunity.
Cell death and differentiation 2008;15(1):80-8.
2008: Huber Veronica; Filipazzi Paola; Iero Manuela; Fais Stefano; Rivoltini Licia
More insights into the immunosuppressive potential of tumor exosomes.
Journal of translational medicine 2008;6():63.
2007: Maccalli Cristina; Nonaka Daisuke; Piris Adriano; Pende Daniela; Rivoltini Licia; Castelli Chiara; Parmiani Giorgio
NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(24):7459-68.
2007: Iero Manuela; Squarcina Paola; Romero Pedro; Guillaume Philippe; Scarselli Elisa; Cerino Raffaele; Carrabba Matteo; Toutirais Olivier; Parmiani Giorgio; Rivoltini Licia
Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide.
Cancer immunology, immunotherapy : CII 2007;56(12):1979-91.
2007: Parmiani Giorgio; Russo Vincenzo; Marrari Andrea; Cutolo Gianluca; Casati Chiara; Pilla Lorenzo; Maccalli Cristina; Rivoltini Licia; Castelli Chiara
Universal and stemness-related tumor antigens: potential use in cancer immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(19):5675-9.
2007: Filipazzi Paola; Valenti Roberta; Huber Veronica; Pilla Lorenzo; Canese Paola; Iero Manuela; Castelli Chiara; Mariani Luigi; Parmiani Giorgio; Rivoltini Licia
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(18):2546-53.
2007: Daniotti Maria; Vallacchi Viviana; Rivoltini Licia; Patuzzo Roberto; Santinami Mario; Arienti Flavio; Cutolo Gianluca; Pierotti Marco A; Parmiani Giorgio; Rodolfo Monica
Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients.
International journal of cancer. Journal international du cancer 2007;120(11):2439-44.
2007: Valenti Roberta; Huber Veronica; Iero Manuela; Filipazzi Paola; Parmiani Giorgio; Rivoltini Licia
Tumor-released microvesicles as vehicles of immunosuppression.
Cancer research 2007;67(7):2912-5.
2007: Marrari Andrea; Iero Manuela; Pilla Lorenzo; Villa Sergio; Salvioni Roberto; Valdagni Riccardo; Parmiani Giorgio; Rivoltini Licia
Vaccination therapy in prostate cancer.
Cancer immunology, immunotherapy : CII 2007;56(4):429-45.
2007: Parmiani Giorgio; Castelli Chiara; Santinami Mario; Rivoltini Licia
Melanoma immunology: past, present and future.
Current opinion in oncology 2007;19(2):121-7.
2007: Parmiani G; Castelli C; Pilla L; Santinami M; Colombo M P; Rivoltini L
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(2):226-32.
2006: Valenti Roberta; Huber Veronica; Filipazzi Paola; Pilla Lorenzo; Sovena Gloria; Villa Antonello; Corbelli Alessandro; Fais Stefano; Parmiani Giorgio; Rivoltini Licia
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.
Cancer research 2006;66(18):9290-8.
2006: Pilla Lorenzo; Valenti Roberta; Marrari Andrea; Patuzzo Roberto; Santinami Mario; Parmiani Giorgio; Rivoltini Licia
Vaccination: role in metastatic melanoma.
Expert review of anticancer therapy 2006;6(8):1305-18.
2006: Pilla Lorenzo; Patuzzo Roberto; Rivoltini Licia; Maio Michele; Pennacchioli Elisabetta; Lamaj Elda; Maurichi Andrea; Massarut Samuele; Marchianò Alfonso; Santantonio Cristina; Tosi Diego; Arienti Flavio; Cova Agata; Sovena Gloria; Piris Adriano; Nonaka Daisuke; Bersani Ilaria; Di Florio Annabella; Luigi Mariani; Srivastava Pramod K; Hoos Axel; Santinami Mario; Parmiani Giorgio
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
Cancer immunology, immunotherapy : CII 2006;55(8):958-68.
2006: Parmiani Giorgio; De Filippo Annamaria; Pilla Lorenzo; Castelli Chiara; Rivoltini Licia
Heat shock proteins gp96 as immunogens in cancer patients.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2006;22(3):223-7.
2006: Di Pucchio Tiziana; Pilla Lorenzo; Capone Imerio; Ferrantini Maria; Montefiore Enrica; Urbani Francesca; Patuzzo Roberto; Pennacchioli Elisabetta; Santinami Mario; Cova Agata; Sovena Gloria; Arienti Flavio; Lombardo Claudia; Lombardi Arianna; Caporaso Patrizia; D'Atri Stefania; Marchetti Paolo; Bonmassar Enzo; Parmiani Giorgio; Belardelli Filippo; Rivoltini Licia
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Cancer research 2006;66(9):4943-51.
2006: Casati Chiara; Camisaschi Chiara; Rini Francesca; Arienti Flavio; Rivoltini Licia; Triebel Frédéric; Parmiani Giorgio; Castelli Chiara
Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity.
Cancer research 2006;66(8):4450-60.
2006: Lugini Luana; Matarrese Paola; Tinari Antonella; Lozupone Francesco; Federici Cristina; Iessi Elisabetta; Gentile Massimo; Luciani Francesca; Parmiani Giorgio; Rivoltini Licia; Malorni Walter; Fais Stefano
Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells.
Cancer research 2006;66(7):3629-38.
2006: Cassatella Marco A; Huber Veronica; Calzetti Federica; Margotto Daniela; Tamassia Nicola; Peri Giuseppe; Mantovani Alberto; Rivoltini Licia; Tecchio Cristina
Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators.
Journal of leukocyte biology 2006;79(1):123-32.
2005: Parmiani Giorgio; Castelli Chiara; Rivoltini Licia
Chemokine receptor 7, a new player in regulating apoptosis of CD8+ T cells in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7587-8.
2005: Huber Veronica; Fais Stefano; Iero Manuela; Lugini Luana; Canese Paola; Squarcina Paola; Zaccheddu Annamaria; Colone Marisa; Arancia Giuseppe; Gentile Massimo; Seregni Ettore; Valenti Roberta; Ballabio Giuseppina; Belli Filiberto; Leo Ermanno; Parmiani Giorgio; Rivoltini Licia
Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape.
Gastroenterology 2005;128(7):1796-804.
2005: Di Stasi Delia; Vallacchi Viviana; Campi Valentina; Ranzani Tiziana; Daniotti Maria; Chiodini Elena; Fiorentini Silvia; Greeve Isabell; Prinetti Alessandro; Rivoltini Licia; Pierotti Marco A; Rodolfo Monica
DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress-induced apoptosis.
International journal of cancer. Journal international du cancer 2005;115(2):224-30.
2005: De Cesare Michelandrea; Perego Paola; Righetti Sabina C; Pratesi Graziella; Carenini Nives; Rivoltini Licia; Zupi Gabriella; Del Bufalo Donatella; Balsari Andrea; Zunino Franco
Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts.
European journal of cancer (Oxford, England : 1990) 2005;41(8):1213-22.
2005: Pilla Lorenzo; Squarcina Paola; Coppa Jorgelina; Mazzaferro Vincenzo; Huber Veronica; Pende Daniela; Maccalli Cristina; Sovena Gloria; Mariani Luigi; Castelli Chiara; Parmiani Giorgio; Rivoltini Licia
Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96.
Cancer research 2005;65(9):3942-9.
2005: Rivoltini Licia; Canese Paola; Huber Veronica; Iero Manuela; Pilla Lorenzo; Valenti Roberta; Fais Stefano; Lozupone Francesco; Casati Chiara; Castelli Chiara; Parmiani Giorgio
Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?
Expert opinion on biological therapy 2005;5(4):463-76.
2005: Dalerba Piero; Guiducci Cristiana; Poliani Pietro Luigi; Cifola Ingrid; Parenza Mariella; Frattini Milo; Gallino Gianfrancesco; Carnevali Ileana; Di Giulio Ilvia; Andreola Salvatore; Lombardo Claudia; Rivoltini Licia; Schweighoffer Tamás; Belli Filiberto; Colombo Mario P; Parmiani Giorgio; Castelli Chiara
Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells.
Cancer research 2005;65(6):2321-9.
2004: Parmiani Giorgio; Testori Alessandro; Maio Michele; Castelli Chiara; Rivoltini Licia; Pilla Lorenzo; Belli Filiberto; Mazzaferro Vincenzo; Coppa Jorgelina; Patuzzo Roberto; Sertoli Mario R; Hoos Axel; Srivastava Pramod K; Santinami Mario
Heat shock proteins and their use as anticancer vaccines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8142-6.
2004: Luciani Francesca; Spada Massimo; De Milito Angelo; Molinari Agnese; Rivoltini Licia; Montinaro Annalisa; Marra Manuela; Lugini Luana; Logozzi Mariantonia; Lozupone Francesco; Federici Cristina; Iessi Elisabetta; Parmiani Giorgio; Arancia Giuseppe; Belardelli Filippo; Fais Stefano
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
Journal of the National Cancer Institute 2004;96(22):1702-13.
2004: Tosi Diego; Valenti Roberta; Cova Agata; Sovena Gloria; Huber Veronica; Pilla Lorenzo; Arienti Flavio; Belardelli Filippo; Parmiani Giorgio; Rivoltini Licia
Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(9):5363-70.
2004: Tecchio Cristina; Huber Veronica; Scapini Patrizia; Calzetti Federica; Margotto Daniela; Todeschini Giuseppe; Pilla Lorenzo; Martinelli Giovanni; Pizzolo Giovanni; Rivoltini Licia; Cassatella Marco A
IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells.
Blood 2004;103(10):3837-44.
2004: Castelli Chiara; Rivoltini Licia; Rini Francesca; Belli Filiberto; Testori Alessandro; Maio Michele; Mazzaferro Vincenzo; Coppa Jorgelina; Srivastava Pramod K; Parmiani Giorgio
Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer.
Cancer immunology, immunotherapy : CII 2004;53(3):227-33.
2004: Lozupone Francesco; Pende Daniela; Burgio Vito Lelio; Castelli Chiara; Spada Massimo; Venditti Massimo; Luciani Francesca; Lugini Luana; Federici Cristina; Ramoni Carlo; Rivoltini Licia; Parmiani Giorgio; Belardelli Filippo; Rivera Paola; Marcenaro Stefania; Moretta Lorenzo; Fais Stefano
Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice.
Cancer research 2004;64(1):378-85.
2003: Parmiani Giorgio; Castelli Chiara; Rivoltini Licia; Casati Chiara; Tully Glenn A; Novellino Luisa; Patuzzo Andrea; Tosi Diego; Anichini Andrea; Santinami Mario
Immunotherapy of melanoma.
Seminars in cancer biology 2003;13(6):391-400.
2003: Lugini Luana; Lozupone Francesco; Matarrese Paola; Funaro Cristina; Luciani Francesca; Malorni Walter; Rivoltini Licia; Castelli Chiara; Tinari Antonella; Piris Adriano; Parmiani Giorgio; Fais Stefano
Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin.
Laboratory investigation; a journal of technical methods and pathology 2003;83(11):1555-67.
2003: Rodolfo Monica; Luksch Roberto; Stockert Elisabeth; Chen Yao-Tseng; Collini Paola; Ranzani Tiziana; Lombardo Claudia; Dalerba Piero; Rivoltini Licia; Arienti Flavio; Fossati-Bellani Franca; Old Lloyd J; Parmiani Giorgio; Castelli Chiara
Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
Cancer research 2003;63(20):6948-55.
2003: Rivoltini Licia; Castelli Chiara; Carrabba Matteo; Mazzaferro Vincenzo; Pilla Lorenzo; Huber Veronica; Coppa Jorgelina; Gallino Gianfrancesco; Scheibenbogen Carmen; Squarcina Paola; Cova Agata; Camerini Roberto; Lewis Jonathan J; Srivastava Pramod K; Parmiani Giorgio
Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(7):3467-74.
2003: Mazzaferro Vincenzo; Coppa Jorgelina; Carrabba Matteo G; Rivoltini Licia; Schiavo Marcello; Regalia Enrico; Mariani Luigi; Camerini Tiziana; Marchianò Alfonso; Andreola Salvatore; Camerini Roberto; Corsi Marco; Lewis Jonathan J; Srivastava Pramod K; Parmiani Giorgio
Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(9):3235-45.
2003: Casati Chiara; Dalerba Piero; Rivoltini Licia; Gallino Gianfrancesco; Deho Paola; Rini Francesca; Belli Filiberto; Mezzanzanica Delia; Costa Aurora; Andreola Salvatore; Leo Ermanno; Parmiani Giorgio; Castelli Chiara
The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients.
Cancer research 2003;63(15):4507-15.
2003: Mantovani Stefania; Garbelli Silvia; Palermo Belinda; Campanelli Rita; Brazzelli Valeria; Borroni Giovanni; Martinetti Myriam; Benvenuto Federica; Merlini Giampaolo; della Cuna Gioacchino Robustelli; Rivoltini Licia; Giachino Claudia
Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient.
The Journal of investigative dermatology 2003;121(2):308-14.
2003: Parmiani G; Pilla L; Castelli C; Rivoltini L
Vaccination of patients with solid tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(6):817-24.
2003: Novellino Luisa; Renkvist Nicolina; Rini Francesca; Mazzocchi Arabella; Rivoltini Licia; Greco Angela; Deho Paola; Squarcina Paola; Robbins Paul F; Parmiani Giorgio; Castelli Chiara
Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(12):6363-70.
2003: Carrabba Matteo G; Castelli Chiara; Maeurer Markus J; Squarcina Paola; Cova Agata; Pilla Lorenzo; Renkvist Nicolina; Parmiani Giorgio; Rivoltini Licia
Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
Cancer research 2003;63(7):1560-7.
2003: Lozupone Francesco; Rivoltini Licia; Luciani Francesca; Venditti Massimo; Lugini Luana; Cova Agata; Squarcina Paolo; Parmiani Giorgio; Belardelli Filippo; Fais Stefano
Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
European journal of immunology 2003;33(2):556-66.
2002: Rivoltini Licia; Carrabba Matteo; Huber Veronica; Castelli Chiara; Novellino Luisa; Dalerba Piero; Mortarini Roberta; Arancia Giuseppe; Anichini Andrea; Fais Stefano; Parmiani Giorgio
Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.
Immunological reviews 2002;188():97-113.
2002: Palermo B; Campanelli R; Garbelli S; Mantovani S; Robustelli Della Cuna G; Necker A; Manganoni A M; Carella G; Rivoltini L; Lantelme E; Giachino C
Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a qualitative analysis.
Melanoma research 2002;12(5):491-8.
2002: Belli Filiberto; Testori Alessandro; Rivoltini Licia; Maio Michele; Andreola Giovanna; Sertoli Mario Roberto; Gallino Gianfrancesco; Piris Adriano; Cattelan Alessandro; Lazzari Ivano; Carrabba Matteo; Scita Giorgio; Santantonio Cristina; Pilla Lorenzo; Tragni Gabrina; Lombardo Claudia; Arienti Flavio; Marchianò Alfonso; Queirolo Paola; Bertolini Francesco; Cova Agata; Lamaj Elda; Ascani Lucio; Camerini Roberto; Corsi Marco; Cascinelli Natale; Lewis Jonathan J; Srivastava Pramod; Parmiani Giorgio
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(20):4169-80.
2002: Parmiani Giorgio; Sensi Marialuisa; Castelli Chiara; Rivoltini Licia; Anichini Andrea
T-cell response to unique and shared antigens and vaccination of cancer patients.
Cancer immunity : a journal of the Academy of Cancer Immunology 2002;2():6.
2002: Parmiani Giorgio; Castelli Chiara; Dalerba Piero; Mortarini Roberta; Rivoltini Licia; Marincola Francesco M; Anichini Andrea
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
Journal of the National Cancer Institute 2002;94(11):805-18.
2002: Andreola Giovanna; Rivoltini Licia; Castelli Chiara; Huber Veronica; Perego Paola; Deho Paola; Squarcina Paola; Accornero Paola; Lozupone Francesco; Lugini Luana; Stringaro Annarita; Molinari Agnese; Arancia Giuseppe; Gentile Massimo; Parmiani Giorgio; Fais Stefano
Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.
The Journal of experimental medicine 2002;195(10):1303-16.
2001: Mazzocchi A; Melani C; Rivoltini L; Castelli C; Del Vecchio M; Lombardo C; Colombo M P; Parmiani G
Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes.
Cancer immunology, immunotherapy : CII 2001;50(4):199-211.
2001: Castelli C; Ciupitu A M; Rini F; Rivoltini L; Mazzocchi A; Kiessling R; Parmiani G
Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells.
Cancer research 2001;61(1):222-7.
2001: Parmiani G; Castelli C; Dalerba P; Rivoltini L
T cell response to tumor antigens and its therapeutic use in cancer patients.
Advances in experimental medicine and biology 2001;495():403-10.
2000: Carrabba M; Parmiani G; Rivoltini L
Cancer vaccines.
Tumori 2000;86(5 Suppl 2):S33-7.
2000: Parmiani G; Rivoltini L; Andreola G; Carrabba M
Cytokines in cancer therapy.
Immunology letters 2000;74(1):41-4.
2000: Lozupone F; Luciani F; Venditti M; Rivoltini L; Pupa S; Parmiani G; Belardelli F; Fais S
Murine granulocytes control human tumor growth in SCID mice.
International journal of cancer. Journal international du cancer 2000;87(4):569-73.
2000: Castelli C; Rivoltini L; Andreola G; Carrabba M; Renkvist N; Parmiani G
T-cell recognition of melanoma-associated antigens.
Journal of cellular physiology 2000;182(3):323-31.
1999: Arienti F; Belli F; Napolitano F; Sulé-Suso J; Mazzocchi A; Gallino G F; Cattelan A; Santantonio C; Rivoltini L; Melani C; Colombo M P; Cascinelli N; Maio M; Parmiani G;
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells.
Human gene therapy 1999;10(18):2907-16.
1999: Castelli C; Tarsini P; Mazzocchi A; Rini F; Rivoltini L; Ravagnani F; Gallino F; Belli F; Parmiani G
Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(3):1739-48.
1999: Rivoltini L; Squarcina P; Loftus D J; Castelli C; Tarsini P; Mazzocchi A; Rini F; Viggiano V; Belli F; Parmiani G
A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy.
Cancer research 1999;59(2):301-6.
1998: Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo M P; Parmiani G
Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(3):1220-30.
1998: Hicklin D J; Wang Z; Arienti F; Rivoltini L; Parmiani G; Ferrone S
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
The Journal of clinical investigation 1998;101(12):2720-9.
1998: Loftus D J; Squarcina P; Nielsen M B; Geisler C; Castelli C; Odum N; Appella E; Parmiani G; Rivoltini L
Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35).
Cancer research 1998;58(11):2433-9.
1998: Castelli C; Mazzocchi A; Rini F; Tarsini P; Rivoltini L; Maio M; Gallino G; Belli F; Parmiani G
Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients.
European journal of immunology 1998;28(4):1143-54.
1998: Rivoltini L; Loftus D J; Squarcina P; Castelli C; Rini F; Arienti F; Belli F; Marincola F M; Geisler C; Borsatti A; Appella E; Parmiani G
Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity.
Critical reviews in immunology 1998;18(1-2):55-63.
1997: Castelli C; Rivoltini L; Mazzocchi A; Parmiani G
T-cell recognition of melanoma antigens and its therapeutic applications.
International journal of clinical & laboratory research 1997;27(2):103-10.
1996: Arienti F; Sulé-Suso J; Belli F; Mascheroni L; Rivoltini L; Melani C; Maio M; Cascinelli N; Colombo M P; Parmiani G
Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells.
Human gene therapy 1996;7(16):1955-63.
1996: Mazzocchi A; Storkus W J; Traversari C; Tarsini P; Maeurer M J; Rivoltini L; Vegetti C; Belli F; Anichini A; Parmiani G; Castelli C
Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(7):3030-8.
1996: Player M A; Barracchini K C; Simonis T B; Rivoltini L; Arienti F; Castelli C; Mazzocchi A; Belli F; Parmiani G; Marincola F M
Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(5):357-63.
1996: Loftus D J; Castelli C; Clay T M; Squarcina P; Marincola F M; Nishimura M I; Parmiani G; Appella E; Rivoltini L
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).
The Journal of experimental medicine 1996;184(2):647-57.
1996: Marincola F M; Rivoltini L; Salgaller M L; Player M; Rosenberg S A
Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(4):266-77.
1996: Marincola F M; Hijazi Y M; Fetsch P; Salgaller M L; Rivoltini L; Cormier J; Simonis T B; Duray P H; Herlyn M; Kawakami Y; Rosenberg S A
Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(3):192-205.
1996: Rivoltini L; Loftus D J; Barracchini K; Arienti F; Mazzocchi A; Biddison W E; Salgaller M L; Appella E; Parmiani G; Marincola F M
Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(10):3882-91.
1996: Parmiani G; Arienti F; Sulé-Suso J; Melani C; Colombo M P; Ramakrishna V; Belli F; Mascheroni L; Rivoltini L; Cascinelli N
Cytokine-based gene therapy of human tumors. An overview.
Folia biologica 1996;42(6):305-9.
1995: Marincola F M; Shamamian P; Rivoltini L; Salgaller M; Cormier J; Restifo N P; Simonis T B; Venzon D; White D E; Parkinson D R
HLA associations in the antitumor response against malignant melanoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(4):242-52.
1995: Salgaller M L; Afshar A; Marincola F M; Rivoltini L; Kawakami Y; Rosenberg S A
Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
Cancer research 1995;55(21):4972-9.
1995: Rivoltini L; Barracchini K C; Viggiano V; Kawakami Y; Smith A; Mixon A; Restifo N P; Topalian S L; Simonis T B; Rosenberg S A
Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.
Cancer research 1995;55(14):3149-57.
1995: Sensi M; Traversari C; Radrizzani M; Salvi S; Maccalli C; Mortarini R; Rivoltini L; Farina C; Nicolini G; Wölfel T
Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(12):5674-8.
1995: Robbins P F; el-Gamil M; Li Y F; Topalian S L; Rivoltini L; Sakaguchi K; Appella E; Kawakami Y; Rosenberg S A
Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(11):5944-50.
1995: Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins P F; Marincola F M; Salgaller M L; Yannelli J R; Appella E
Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(5):2257-65.
1994: Cole D J; Weil D P; Shamamian P; Rivoltini L; Kawakami Y; Topalian S; Jennings C; Eliyahu S; Rosenberg S A; Nishimura M I
Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope.
Cancer research 1994;54(20):5265-8.
1994: Topalian S L; Rivoltini L; Mancini M; Markus N R; Robbins P F; Kawakami Y; Rosenberg S A
Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(20):9461-5.
1994: Boiardi A; Silvani A; Ruffini P A; Rivoltini L; Parmiani G; Broggi G; Salmaggi A
Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients.
Cancer immunology, immunotherapy : CII 1994;39(3):193-7.
1994: Topalian S L; Rivoltini L; Mancini M; Ng J; Hartzman R J; Rosenberg S A
Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
International journal of cancer. Journal international du cancer 1994;58(1):69-79.
1994: Kawakami Y; Eliyahu S; Sakaguchi K; Robbins P F; Rivoltini L; Yannelli J R; Appella E; Rosenberg S A
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
The Journal of experimental medicine 1994;180(1):347-52.
1994: Kawakami Y; Eliyahu S; Delgado C H; Robbins P F; Rivoltini L; Topalian S L; Miki T; Rosenberg S A
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(9):3515-9.
1993: Ruffini P A; Rivoltini L; Silvani A; Boiardi A; Parmiani G
Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.
Cancer immunology, immunotherapy : CII 1993;36(6):409-16.
1993: Arienti F; Belli F; Rivoltini L; Gambacorti-Passerini C; Furlan L; Mascheroni L; Prada A; Rizzi M; Marchesi E; Vaglini M
Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2.
Cancer immunology, immunotherapy : CII 1993;36(5):315-22.
1993: Melani C; Mattia G F; Silvani A; Carè A; Rivoltini L; Parmiani G; Colombo M P
Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes.
Blood 1993;81(10):2744-9.
1993: Rivoltini L; Viggiano V; Spinazzè S; Santoro A; Colombo M P; Takatsu K; Parmiani G
In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5.
International journal of cancer. Journal international du cancer 1993;54(1):8-15.
1993: Viviani S; Salvini P M; Bidoli P; Camerini E; Spinazzé S; Arienti F; Rivoltini L; Motta V
Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer.
The International journal of biological markers 1993;8(1):21-4.
1993: Caraceni A; Martini C; Belli F; Mascheroni L; Rivoltini L; Arienti F; Cascinelli N
Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration.
European journal of cancer (Oxford, England : 1990) 1993;29A(9):1266-9.
1992: Belli F; Arienti F; Rivoltini L; Santinami M; Mascheroni L; Prada A; Ammatuna M; Marchesi E; Parmiani G; Cascinelli N
Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study.
Melanoma research 1992;2(4):263-71.
1992: Rivoltini L; Cattoretti G; Arienti F; Mastroianni A; Parmiani G
CEA and NCA expressed by colon carcinoma cells affect their interaction with and lysability by activated lymphocytes.
The International journal of biological markers 1992;7(3):143-7.
1992: Arienti F; Gambacorti-Passerini C; Borin L; Rivoltini L; Orazi A; Pogliani E M; Corneo G; Parmiani G
Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(2):155-62.
1992: Rivoltini L; Arienti F; Orazi A; Cefalo G; Gasparini M; Gambacorti-Passerini C; Fossati-Bellani F; Parmiani G
Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype.
Cancer immunology, immunotherapy : CII 1992;34(4):241-51.
1991: Spinazzé S; Viviani S; Bidoli P; Rovelli F; Palmer P; Franks C R; Arienti F; Rivoltini L; Parmiani G
Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients.
Tumori 1991;77(6):496-9.
1991: Gambacorti-Passerini C; Rivoltini L; Fizzotti M; Rodolfo M; Sensi M L; Castelli C; Orazi A; Polli N; Bregni M; Siena S
Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells.
British journal of haematology 1991;78(2):197-205.
1991: Melani C; Rivoltini L; Parmiani G; Calabretta B; Colombo M P
Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb.
Cancer research 1991;51(11):2897-901.
1991: Rivoltini L; Cattoretti G; Arienti F; Mastroianni A; Melani C; Colombo M P; Parmiani G
The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype.
International journal of cancer. Journal international du cancer 1991;47(5):746-54.
1990: Squadrelli-Saraceno M; Rivoltini L; Cantù G; Ravagnani F; Parmiani G; Molinari R
Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2.
Tumori 1990;76(6):566-71.
1990: Rivoltini L; Colombo M P; Supino R; Ballinari D; Tsuruo T; Parmiani G
Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line.
International journal of cancer. Journal international du cancer 1990;46(4):727-32.
1990: Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso M I; Cantù G; Molinari R; Orazi A; Parmiani G
In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
Cancer research 1990;50(17):5551-7.
1989: Gambacorti-Passerini C; Rivoltini L; Radrizzani M; Belli F; Sciorelli G; Ravagnani F; Galazka A R; Cascinelli N; Parmiani G
Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.
Cancer research 1989;49(18):5230-4.
1989: Rivoltini L; Gambacorti-Passerini C; Supino R; Parmiani G
Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance.
International journal of cancer. Journal international du cancer 1989;43(5):880-5.
1989: Parmiani G; Rivoltini L
In vitro lymphocyte response to autologous melanoma: clues in designing new adoptive immunotherapy protocols.
European journal of cancer & clinical oncology 1989;25 Suppl 3():S37-9.
1988: Gambacorti-Passerini C; Rivoltini L; Radrizzani M; Supino R; Mariani M; Parmiani G
Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2-activated lymphocytes (LAK).
Cancer metastasis reviews 1988;7(4):335-45.
1988: Gambacorti-Passerini C; Radrizzani M; Rivoltini L; Marchesi E; Ravagnani F; Sciorelli G; Cascinelli N; Parmiani G
A new procedure for large scale production and freezing of lymphokine activated killer (LAK) cells to be used in adoptive immunotherapy of cancer.
Tumori 1988;74(5):523-30.
1988: Gambacorti-Passerini C; Rivoltini L; Supino R; Mariani M; Parmiani G
Differential lysis of melanoma clones by autologous recombinant interleukin 2-activated lymphocytes. Relationship with spontaneous resistance to doxorubicin (Dx).
International journal of cancer. Journal international du cancer 1988;42(4):544-8.
1988: Gambacorti-Passerini C; Rivoltini L; Supino R; Rodolfo M; Radrizzani M; Fossati G; Parmiani G
Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes.
Cancer research 1988;48(9):2372-6.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Licia Rivoltini

Research Profile (preview)

Disorders

Chemicals & Drugs

Anatomy

Physiology

Procedures

Genes & Molecular Sequences

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Licia Rivoltini (preview)

All Publications